Table 4.
ORR and DOR per BICR in the Asian subpopulation of CheckMate 9LA
| NIVO + IPI + chemoa (n = 28) | Chemob (n = 30) | |
|---|---|---|
| ORR, n (%) | 16 (57) | 7 (23) |
| Best overall response, n (%) | ||
| Complete response | 2 (7) | 0 |
| Partial response | 14 (50) | 7 (23) |
| Stable disease | 9 (32) | 16 (53) |
| Progressive disease | 3 (11) | 5 (17) |
| Could not be determined | 0 | 2 (7) |
| Disease control rate, n (%) | 25 (89) | 23 (77) |
| Time to response, median (range), months | 1.5 (1.2–9.5) | 2.8 (1.2–5.4) |
| DOR, median (95% CI), months | 7.0 (2.8–11.0) | 4.4 (2.8–NR) |
BICR blinded independent central review, Chemo chemotherapy, CI confidence interval, DOR duration of response, IPI ipilimumab, n number of patients, NIVO nivolumab, NR not reached, ORR objective response rate
aNivolumab plus ipilimumab combined with chemotherapy (2 cycles)
bChemotherapy alone (4 cycles, with optional pemetrexed maintenance for nonsquamous histology)